Cyclic nucleotide phosphodiesterase assay technology

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 49, 2010, Pages

  MacKenzie, S J ^a   Hastings, S F ^a   Wells, C ^a  

^a Scottish Biomedical   (United Kingdom)

Author keywords

PDE assay protocols; PDE assay technologies; phosphodiesterase

Indexed keywords

CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE;

CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); DILUTION; DRUG DEGRADATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME MECHANISM; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; IC 50; ISOTOPE LABELING; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; VALIDATION PROCESS;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; CHROMATOGRAPHY, AFFINITY; ENZYME ASSAYS; HUMANS; HYDROLYSIS; RADIOLIGAND ASSAY; SPECIMEN HANDLING; SUBSTRATE SPECIFICITY; TITRIMETRY;

EID: 77953821787     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0312s49     Document Type: Review

References (11)

1. Bella, A.J., Deyoung, L.X., Al-Numi, M., and, Brock, G.B., 2007. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur. Urol. 52: 990-1005.
2. Conti, M., and, Beavo, J., 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76: 481-511.
3. Francis, S.H., Turko, I.V., and, Corbin, J.D., 2001. Cyclic nucleotide Phosphodiesterases: Relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65: 1-52.
4. Gupta, R., Kumar, G., and, Kumar, R.S., 2005. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: Phosphodiesterases and drug selectivity. Methods Find. Exp. Clin. Pharmacol. 27: 101-118.
5. Gibson, L.C., Hastings, S.F., McPhee, I., Clayton, R.A., Darroch, C., Mackenzie, A., MacKenzie, F.L., Nagasawa, M., Stevens, P.A., and, MacKenzie, S.J., 2006. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol. 538: 39-42.
6. Huang, W., Zhang, Y., and, Sportsman, J.R., 2002. A fluorescence polarization assay for cyclic nucleotide phosphodiesterases. J. Biomol. Screen. 7: 215-222.
7. Kumar, M., and, Bhattacharya V., 2007. Cilostazol: A new drug in the treatment intermittent claudication. Recent Patents Cardiovasc. Drug Discov. 2: 181-185.
8. Omori, K., and, Kotera, J., 2007. Overview of PDEs and their regulation. Circ. Res. 100: 309-327.
9. Thompson, W.J., and, Appleman, M.M., 1971. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316.
10. Wu, G., Yuan, Y., and, Hodge, C.N., 2003. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J. Biomol. Screen. 8: 694-700.
11. Yu, J., Wolda, S.L., Frazier, A.L., Florio, V.A., Martins, T.J., Snyder, P.B., Harris, E.A., McCaw, K.N., Farrell, C.A., Steiner, B., Bentley, J.K., Beavo, J.A., Ferguson, K., and, Gelinas, R., 1997. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal 9: 519-529.